Hey readers!
This week brought the kind of news the celiac community has been waiting years to hear: a drug that let trial participants eat gluten daily for six weeks while their gut stayed largely protected. Below we break down exactly what Teva reported, the actual biopsy numbers, who ran the recruiting, and how it stacks up against a competing program that just changed hands. A few concrete places to go: the Celiac Disease Foundation's writeup, the full trial numbers at AllSci, and Teva's official topline release.
🔬 The headline: Teva's anti-IL-15 antibody cleared Phase 2a
Teva's anti-IL-15 antibody cuts gluten-induced intestinal damage in Phase IIa celiac disease trial is the piece to read if you want the real numbers rather than a press-release gloss. In a randomized, double-blind, placebo-controlled trial of 50 adults already on a gluten-free diet, a single subcutaneous dose of TEV-'408 was followed by a six-week daily gluten challenge, and at week 8 the drug met its primary endpoint.
– AllSci
Here is what "met the endpoint" actually meant. The primary measure was the villous height-to-crypt depth ratio, a biopsy readout of how intact the intestinal lining is. Per AllSci, the treatment group's change from baseline was -0.43 versus -0.88 for placebo (treatment difference 0.45; 95% CI: 0.06-0.84; p<0.05). In plainer terms, both groups took some damage from the gluten, but the treated group took roughly half as much.
The inflammation signal was even more striking. Intraepithelial lymphocyte density, the immune-cell buildup that flags active celiac damage, rose by 27.60 in the placebo arm but by just 0.37 with TEV-'408. Patients on the drug also reported lower gastrointestinal symptom scores, so this was not only a tissue effect but a felt-better effect.
💡 Why IL-15 is the target that matters
Teva's Anti-IL-15 Antibody Clears Phase 2 in Celiac Disease does the best job of explaining the mechanism and why a positive Phase 2 carries weight here. Rather than trying to block gluten recognition, TEV-'408 targets interleukin-15, a cytokine that activates and sustains the immune cells doing the actual damage to the gut lining.
– Biotech Insider
That distinction matters for how you should read this. The antibody does not stop your body from recognizing gluten; it dampens the downstream immune response that recognition sets off. As Biotech Insider notes, celiac has a long history of ambiguous or failed programs and notoriously difficult biopsy endpoints, which is part of why hitting a clear biopsy signal in this trial drew attention.
The same piece is candid about what still stands in the way, and it is worth internalizing before anyone gets ahead of the data:
Interleukin-15 blockade is also being explored across other immune-mediated conditions, so a validated antibody has optionality beyond celiac. That is the part of the story that turns a single readout into a platform argument - and the part that will draw the most scrutiny, because it is also the easiest to oversell before phase 3 data exist.
Markets took it in stride, too. Biotech Insider reported Teva shares traded at 36.36, down 0.71% on Sept. 4, 2026, though Reuters noted the U.S.-listed shares were up nearly 3% in early trading right after the news. A modest move for a positive readout tells you investors are pricing in how far Phase 3 still is.
🩺 What this means if you or a patient live with celiac
Teva Pharmaceuticals Announces Positive Phase 2a Results for Investigational Celiac Disease Treatment is the version we would hand to patients and parents, and it includes an important detail: the Celiac Disease Foundation helped recruit participants for this study.
– Celiac Disease Foundation
CEO Marilyn Geller struck exactly the right tone, hopeful without overselling:
The results from this study are an encouraging sign that we are getting closer to discovering therapies outside of the gluten-free diet. We are grateful to the patients who participated in this study and to everyone in our community who continues to help advance celiac disease research.
We want to underline the CDF's caveat, because it is the honest bottom line: TEV-'408 is still investigational and is not an approved treatment. More research is needed to understand its safety and effectiveness in larger, longer trials. There are currently no FDA-approved drugs for celiac disease, and per Reuters the condition affects more than 3 million people in the United States, so the unmet need is real. Teva has said participants will be followed through week 80 to gauge durability and safety, and the antibody already holds FDA Fast Track designation granted in May 2025.
One more piece of context worth reading: Teva drug meets endpoints in celiac disease trial captures Teva's own framing of the effort. Dr. Eric Hughes, Teva's chief medical officer, put the ambition this way:
A strict gluten-free diet has long been the only option for people living with celiac disease. Yet, even with strict adherence to a gluten-free diet, many continue to experience symptoms, intestinal damage and a significant impact on their daily lives.
Teva is positioning TEV-'408 as a "pipeline-in-a-product," citing encouraging early findings in vitiligo as well. The plan from here, per MedCity News, is a multiple-dose Phase 2 to define a regimen before committing to Phase 3.
⚗️ The competitive picture is getting crowded
Teva is not alone in the immune-pathway approach to celiac. argenx Completes Acquisition of Forte Biosciences, Inc. closed on August 27, 2026, folding FB102, a first-in-class anti-CD122 antibody with proof-of-concept in both vitiligo and celiac, into argenx's pipeline. The deal was a cash tender offer at $77.00 per share.
– Market Minute
MedCity News also flags First Track Biotherapeutics' ANB033 in the mix. CD122 sits on the same IL-15 signaling axis, so several companies are now converging on the immune-driven damage rather than the gluten trigger itself. Competition tends to accelerate answers, and for a disease with zero approved drugs, more shots on goal is genuinely good news.
🧫 Also worth your time this month
A few other developments that speak to how celiac is understood and monitored:
Blood Test Could Spot Gut Damage in Celiac Disease: A case-control study found inflammatory serum proteins that tracked antibody titers and biopsy severity. After a median of 12.4 months gluten-free, most declined but nine stayed elevated, hinting at persistent low-grade inflammation even in patients who seem to be improving. – Medscape
Machine learning reveals HLA-DQ2.5's impact on naïve T-cell receptors: A useful reminder that a model can look like it is diagnosing celiac when it is really just detecting the inherited HLA-DQ2.5 risk gene. When the analysis was limited to DQ2.5-positive people, celiac classification dropped to about 0.5 balanced accuracy, no better than chance. – Scienmag
Rare Lung Condition Expands Celiac Disease's Known Complications: A biopsy-proven case of progressive pulmonary fibrosis requiring a double lung transplant in a 55-year-old with long-standing celiac raises the question of whether gluten-driven autoimmunity can reach beyond the gut. A single case, but one clinicians will want on their radar. – Scienmag
Jennie Garth Says She 'Just Found Out I'm Celiac': The actress described years of unexplained symptoms before diagnosis, a familiar story that helps normalize testing for anyone dismissing chronic discomfort. – PEOPLE via Yahoo
🍽️ A living-gluten-free note
Until a therapy like TEV-'408 crosses the finish line, the gluten-free diet remains the only management tool, and eating out safely is still the hard part. We are not sponsored by them, but Find Me Gluten Free stays on our shortlist for scouting restaurants and travel options with real reviews from other celiac diners. Worth a bookmark for your next trip.
That is the issue. The takeaway we would leave you with: this is a meaningful step, not a finish line, and the next real signals come with full Phase 2 data and a Phase 3 decision. We will keep watching.